MiMedx Group (MDXG) Osake Kurssi
MiMedx Group Kurssi
Viimeisten 15 vuoden aikana MiMedx Groupn liikevaihto kasvoi 51,9 % vuodessa ja ylsi 418,63 M USD:een. Osakekohtainen tulos on kasvanut 17,6 % vuodessa viimeisten 11 vuoden aikana. MiMedx Groupn nettomarginaali 11,6 % on noussut verrattuna −5,1 %:iin muutama vuosi sitten. MiMedx Groupn 12 kuukauden konsensustavoitehinta on 8,00 USD, noin yli kurssia 65,8 %. 11 analyytikosta 10 suosittaa ostoa — kokonaiskonsensus on Osta.
MiMedx Group osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
MiMedx Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset MiMedx Group -osakkeesta
MiMedx Group Inc. operates as a regenerative medicine company, focused on developing and commercializing therapeutic biologics utilizing human placental tissues. The company's business model revolves around the research, development, manufacturing, and distribution of innovative biomaterial solutions for various therapeutic areas. MiMedx Group Inc. harnesses the regenerative properties of human placental tissues to create and provide safe and effective biologic products for wound care, orthopedic, surgical, and sports medicine applications. By leveraging advanced biotechnology, MiMedx aims to improve patient outcomes and enhance the natural healing process. Through its comprehensive and innovative business model, MiMedx Group Inc. strives to make a positive impact in the field of regenerative medicine.
MiMedx Group Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of MiMedx Group Inc in the market include Organogenesis Holdings Inc, Osiris Therapeutics Inc, and Kerecis Limited.
MiMedx Group Inc is a biopharmaceutical company specializing in regenerative medicine. Founded in 2008, MiMedx focuses on developing and commercializing innovative technologies for tissue repair and healing. The company's portfolio includes products derived from human placental tissue, such as AmnioFix and EpiFix, which have shown great potential in treating various chronic and acute wounds. MiMedx Group Inc has made significant strides in the field of regenerative medicine, earning a reputation for its dedication to patient healing and improving quality of life. With a strong focus on research and development, MiMedx remains committed to advancing tissue regeneration and expanding its product offerings.
MiMedx Group Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully received FDA approval for its flagship product, EpiFix, a revolutionary wound healing therapy. This milestone marked a breakthrough in the treatment of chronic wounds and positioned MiMedx as an industry leader. Additionally, MiMedx reached a major milestone when it expanded its product portfolio, launching AmnioFix, a promising regenerative medicine product. The company's commitment to innovation and extensive clinical research has allowed it to achieve remarkable advancements in the field of wound care, enhancing patients' quality of life and solidifying MiMedx's position as an industry frontrunner.
MiMedx Group Inc is primarily present in the United States.
MiMedx Group Inc represents values of innovation, integrity, and patient-centered care. As a leading biopharmaceutical company, MiMedx is dedicated to developing and commercializing regenerative therapies for various medical conditions. Their corporate philosophy revolves around advancing patient outcomes and improving quality of life through their cutting-edge products and solutions. With a focus on research, clinical excellence, and collaboration, MiMedx aims to redefine the standard of care in the industry. By prioritizing patient needs and employing ethical business practices, MiMedx Group Inc reflects their commitment to delivering transformative healthcare solutions.
Analyytikot asettavat tällä hetkellä MiMedx Group-osakkeelle keskimääräisen tavoitehinnan 8,33 USD (mediaani: 8,00 USD), mikä merkitsee +72,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä MiMedx Group-osaketta: 10 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat MiMedx Group-yhtiöltä 269,79 M USD liikevaihtoa ja −0,07 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla MiMedx Group-osake noteerataan hintaan 4,30 EUR (4,82 USD).
MiMedx Group-osake (MDXG) on listattuna 2 pörssissä, muun muassa: NASDAQ (MDXG), SIX (Zürich) (MXE.SW).
MiMedx Group Inc is a leading provider in the field of tissue regeneration. The company offers various products that contribute to restoring and healing damaged or injured tissue. The company operates in multiple segments and offers its customers a wide range of products and services. The company's main segment is tissue regeneration. Here, MiMedx offers a wide range of products for the treatment of wounds, trauma, burns, and other injuries. Tissue regeneration is an important area of medicine as it can help accelerate the healing of injuries and reduce the risk of complications. Another important segment of the company is biotechnology. MiMedx produces biodegradable materials and biomaterials that can be used for tissue regeneration. Biotechnology is an emerging field in medicine as it reduces the use of synthetic materials and can improve the healing of tissue damage. In the wound care segment, MiMedx offers a wide range of products for the treatment of various types of wounds. This includes ointments, dressings, and special wound dressings that contribute to the support of healing. Another important area is ophthalmology. MiMedx offers products for the treatment of eye diseases. This includes ointments, eye drops, and special contact lenses that contribute to the support of healing. MiMedx's products are used worldwide and utilized by doctors and clinics. The company works closely with medical and research institutions to constantly improve its products and ensure their effectiveness and safety. As a company, MiMedx focuses on innovation and progress. The company is constantly searching for new products and technologies to provide its customers with the best products and services. MiMedx's business model is based on the sale of medical products and services. The company works closely with medical and research institutions to constantly improve its products and ensure their effectiveness and safety. Overall, MiMedx offers its customers a wide range of products and services that can contribute to tissue regeneration and healing of injuries. The company is constantly striving to improve its products and adapt to the needs of its customers. Answer: MiMedx Group Inc is a leading provider in the field of tissue regeneration, offering a wide range of products and services for the restoration and healing of damaged or injured tissue in various medical segments.
odotettu liikevaihto MiMedx Group on 269,79 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto MiMedx Group on −10,48 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
MiMedx Group:n hinta-voitto-suhde (P/E) on tällä hetkellä −68,93. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan MiMedx Group-osakkeen arvostusta.
MiMedx Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,68. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii MiMedx Group-osakkeen arvostuskennuslukuna.
MiMedx Group:n Eulpool-laatuscore on 5/10.
MiMedx Group:n ISIN on US6024961012. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
MiMedx Group:n WKN on A0MS6X. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
MiMedx Group:n ticker on MDXG. Tämä pörssinoteeraus käytetään MiMedx Group-osakkeiden kauppaan pörssissä.
MiMedx Group osake
MiMedx Group vertaisryhmä
MiMedx Group Ticker
MiMedx Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi MiMedx Group:sta
Meidän osakeanalyysimme MiMedx Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut MiMedx Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: